Trial Search Results
Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling
Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in association with the measurement of AlloMap, a non-invasive gene expression test to aid in heart transplant management.
Stanford is currently not accepting patients for this trial.
1. Any heart transplant recipient eligible for initiation and participation in the
Outcomes AlloMap Registry (OAR) Study of regular AlloMap testing.
2. Patients can be enrolled any time as long as they have not had more than 1 prior
3. Written informed consent must be obtained prior to study enrollment. Exclusion
1. Pregnant Women.
Ages Eligible for Study
15 Years - N/A
Genders Eligible for Study